Research on the Irisin Marker in Metabolic Associated Fatty Liver Disease under the Background of Multi-omics Technologies

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500099659

Enrollment

Unknown

Registered

2025-03-26

Start date

2025-04-01

Completion date

Unknown

Last updated

2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MAFLD

Interventions

case group:none

control group:none

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. 18 years <= Age <= 75 years 2. Include patients who meet diagnostic criteria 3. Imaging examination shows no other organic lesions 4. Volunteer to participate in this study

Exclusion criteria

Exclusion criteria: 1. Patients with liver diseases caused by other diseases 2. Previous history of tumors, systemic corticosteroid therapy, biliary obstructive disease, parenteral nutrition, Wilson's disease, hyperthyroidism or hypothyroidism 3. Patients who refuse to participate 4. Patients with severe mental and psychological disorders

Design outcomes

Primary

Measure	Time frame
Irisin;Accuracy;Sensitivity;Specificity;	—

Secondary

Measure	Time frame
Hematology Indicators;	—

Countries

China

Contacts

Public ContactShan Liu

The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)

graystar92@163.com+86 188 0671 5135

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026